Lucid Diagnostics Shares Fall After Pricing of Public Stock Offering

Dow Jones09-10

By Freddy Sebastian

Shares of Lucid Diagnostics fell after its secondary offering of common shares priced.

Its stock slid 17.3% to $1.05 in premarket trading on Wednesday.

The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece.

Lucid also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions.

The offering is expected to close on Thursday.

The company, which is a unit of PAVmed Inc., said it would use the gross proceeds of $25 million for working capital and general corporate purposes.

Write to Freddy Sebastian at freddy.sebastian@wsj.com

(END) Dow Jones Newswires

September 10, 2025 09:00 ET (13:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566601552?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566601552","market":"sg","top_or_hot":-1,"title":"Lucid Diagnostics Shares Fall After Pricing of Public Stock Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> fell after its secondary offering of common shares priced. \n</p>\n<p>\n  Its stock slid 17.3% to $1.05 in premarket trading on Wednesday. \n</p>\n<p>\n  The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/LCID\">Lucid</a> also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions. \n</p>\n<p>\n  The offering is expected to close on Thursday. \n</p>\n<p>\n  The company, which is a unit of <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a>, said it would use the gross proceeds of $25 million for working capital and general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2025 09:00 ET (13:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid Diagnostics Shares Fall After Pricing of Public Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid Diagnostics Shares Fall After Pricing of Public Stock Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-10 21:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> fell after its secondary offering of common shares priced. \n</p>\n<p>\n  Its stock slid 17.3% to $1.05 in premarket trading on Wednesday. \n</p>\n<p>\n  The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/LCID\">Lucid</a> also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions. \n</p>\n<p>\n  The offering is expected to close on Thursday. \n</p>\n<p>\n  The company, which is a unit of <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a>, said it would use the gross proceeds of $25 million for working capital and general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2025 09:00 ET (13:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2566601552","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566601552","pubTimestamp":1757509200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Lucid Diagnostics fell after its secondary offering of common shares priced.Its stock slid 17.3% to $1.05 in premarket trading on Wednesday.The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece.Lucid also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions.The offering is expected to close on Thursday.The company, which is a unit of PAVmed Inc., said it would use the gross proceeds of $25 million for working capital and general corporate purposes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4099":"汽车制造商","LUCD":"LUCID DIAGNOSTICS INC.","BK4082":"医疗保健设备","BK4555":"新能源车","BK4596":"哈里斯概念"},"translate_title":"Lucid Diagnostics股价在公开股票发行定价后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LUCD":0.9},"content_text":"By Freddy Sebastian \n\n\n \n\n\n  Shares of Lucid Diagnostics fell after its secondary offering of common shares priced. \n\n\n  Its stock slid 17.3% to $1.05 in premarket trading on Wednesday. \n\n\n  The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece. \n\n\nLucid also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions. \n\n\n  The offering is expected to close on Thursday. \n\n\n  The company, which is a unit of PAVmed Inc., said it would use the gross proceeds of $25 million for working capital and general corporate purposes. \n\n\n \n\n\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2025 09:00 ET (13:00 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566601552","isCrawlerRequest":true}